Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: A study of three different clones

American Journal of Clinical Pathology

Volumn 134, Issue 5, 2010, Pages 813-819

  Qiu, Jingxin ^a   Kulkarni, Swati ^a   Chandrasekhar, Rameela ^a   Rees, Mark ^b,d   Hyde, Kathryn ^c   Wilding, Gregory ^a   Tan, Dongfeng ^d   Khoury, Thaer ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Leica Microsystems   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Breast cancer; Delay to formalin fixation

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FORMALDEHYDE; PROGESTERONE RECEPTOR; DIAGNOSTIC AGENT; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; BREAST TUMOR; METABOLISM; METHODOLOGY; NONPARAMETRIC TEST; PATHOLOGY; TIME; TISSUE FIXATION;

BREAST NEOPLASMS; FEMALE; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STATISTICS, NONPARAMETRIC; TIME FACTORS; TISSUE ARRAY ANALYSIS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 78049514308     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPVCX83JWMSBNO     Document Type: Article

References (17)

1. Alberts SR, Ingle JN, Roche PR, et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer. 1996;78:764-772.
2. Barnes DM, Harris WH, Smith P, et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996;74:1445-1451. (Pubitemid 26370738)
3. Barnes DM, Millis RR, Beex LV, et al. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer. 1998;34:1677-1682.
4. Selvarajan S, Bay BH, Choo A, et al. Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma. J Histochem Cytochem. 2002;50:1693-1696. (Pubitemid 36078136)
5. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86-92. (Pubitemid 37046374)
6. Arber DA. Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol. 2002;10:183-186.
7. Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005;23:5148-5154.
8. Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008;16:513-520.
9. von Wasielewski R, Mengel M, Nolte M, et al. Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J. 1998;4:33-40.
10. Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22:1457-1467.
11. Newsome JF, Avis FP, Hammond JE, et al. Sampling procedures in estrogen receptor determinations. Ann Surg. 1981;193:549-554.
12. Hasson J, Luhan PA, Kohl MW. Comparison of estrogen receptor levels in breast cancer samples from mastectomy and frozen section specimens. Cancer. 1981;47:138-139. (Pubitemid 11167372)
13. Teicher I, Tinker MA, Auguste LJ, et al. Effect of operative devascularization on estrogen and progesterone receptor levels in breast cancer specimens. Surgery. 1985;98:784-791. (Pubitemid 16164139)
14. Young SC, Burkett RJ, Stewart C. Discrepancy in ER levels of breast carcinoma in biopsy vs mastectomy specimens. J Surg Oncol. 1985;29:54-56. (Pubitemid 15032899)
15. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
16. Kaplan PA, Frazier SR, Loy TS, et al. 1D5 and 6F11: an immunohistochemical comparison of two monoclonal antibodies for the evaluation of estrogen receptor status in primary breast carcinoma. Am J Clin Pathol. 2005;123:276-280.
17. Brock JE, Hornick JL, Richardson AL, et al. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. Am J Clin Pathol. 2009;132:396-401.